Type: stock_drop

Oil prices experienced a decline on Friday after reaching significant weekly gains, driven by geopolitical tensions in the Middle East and concerns over supply disruptions. This volatility highlights the ongoing impact of global events on oil markets, which investors should closely monitor.

Novartis experienced a significant 10% drop in its stock price following the failure of its del-desiran drug in a late-stage trial, marking a troubling trend with three drug trial setbacks in just one week. This decline positions Novartis for its worst trading day on record, raising concerns among investors about the company's pipeline and future prospects.

Tesla's shares fell 6% following a disappointing update on its Cybercab, raising concerns about its competitiveness in the robotaxi market and regulatory compliance.

Investors should note the mixed stock futures and the upcoming August jobs report, which is critical for assessing the labor market's health and its implications for Federal Reserve policy. Additionally, Lululemon's significant stock drop following disappointing earnings highlights challenges in the retail sector.

Broadcom's shares fell 5% after the company provided weaker-than-expected revenue guidance for the upcoming quarter, despite reporting strong earnings and revenue growth for the previous quarter.

Shein's shares dropped 7% on their first day of trading in Hong Kong, reflecting a significant decline in the company's valuation compared to previous estimates and highlighting challenges in its market debut.

BYD's shares dropped nearly 5% after the company reported a decline in revenue and a significant drop in net profit for the first half of the year, highlighting challenges in the competitive Chinese electric vehicle market.

Marvell Technology's shares dropped 8% in premarket trading after the company reported a revenue increase but provided an outlook that fell short of investor expectations, despite a significant year-on-year growth forecast.

Mixue Group's shares dropped over 7% following a report of a 14.7% decline in first-half profit, highlighting the impact of rising costs on the company's profitability. This trend raises concerns for investors about the sustainability of its growth amid increasing expenses.

Boston Scientific is currently facing a cyberattack that is disrupting its operations, leading to a decline in its stock price. This incident is particularly concerning given the company's already weakened financial position earlier this year.